United States Patent 10,064,921: Botulinum Toxin Delivery to Trigeminal Nerve for PTSD

US Patent 10,064,921 claims medical methods that treat post-traumatic stress disorder (PTSD) by directly or locally administering botulinum toxin to trigeminal nerves or their vicinity. The portfolio read-through is dominated by (i) a precise target (trigeminal nerve sensory pathways), (ii) non-intramuscular/local delivery (subdermal, intradermal, transdermal, or injection but not into muscle), and (iii) broad toxin genus coverage (type A and type B) plus wide anatomic lists and dose range.

What is the claim scope, in operational terms?

Core independent claim 1

Claim 1 is a PTSD treatment method with the defining technical elements:

Condition: post-traumatic stress disorder in a patient in need.
Therapeutic act: “directly administering a botulinum toxin to a trigeminal nerve.”
Delivery method: later dependent claims constrain delivery to injection and non-intramuscular modalities.
Mechanism language: “thereby treating the post-traumatic stress disorder.”

Dependent claims expand within a single consistent treatment theme:

Toxin type: type A (claim 2) or type B (claim 3).
Route: injection (claim 4) and non-intramuscular injection (claim 5).
Tissue placement: subdermal / intradermal / transdermal (claim 6).
Target specificity: trigeminal nerve selected from an extended list of ophthalmic/maxillary/mandibular and multiple branches (claim 7).

Independent claim 8

Claim 8 is framed as symptom reduction rather than full treatment, but keeps the same technical spine:

Condition: patient with PTSD.
Outcome: “reducing the occurrence of a symptom of post-traumatic stress disorder.”
Target: locally administering therapeutically effective amount of botulinum toxin to a trigeminal sensory nerve or the vicinity of a trigeminal sensory nerve.
Delivery constraint: “wherein the administering is non-intramuscular.”
Toxin genus: type A (claim 9) or type B (claim 10).
Administration modalities: injection (claim 11) and subdermal/intradermal/transdermal (claim 12).
Dose: between “about 1 unit and about 3,000 units” (claim 14).
Target list: mirrors the trigeminal nerve branch list expanded across sensory distribution (claim 15).

Scope map by claim element

Claim element	Claim 1 (Treatment)	Claim 8 (Symptom reduction)
Disorder	PTSD treatment	PTSD symptom occurrence reduction
Target class	“trigeminal nerve”	“trigeminal sensory nerve” or vicinity
Toxin	botulinum toxin; includes type A and B	botulinum toxin; includes type A and B
Delivery constraint	later claims: injection; non-intramuscular	explicit: non-intramuscular
Placement	later: subdermal/intradermal/transdermal	later: subdermal/intradermal/transdermal
Anatomic specificity	extended trigeminal branch list	same list
Dose	not specified in claims provided for 1	explicit: ~1 to 3,000 units

What is the technical novelty posture implied by the claims?

The claims are structured so that the “novel” differentiator is not botulinum toxin or PTSD alone. The novelty posture is anchored to a combination of:

Trigeminal nerve targeting (including multiple branches and sensory characterization in claim 8)
Non-intramuscular, local delivery (subdermal/intradermal/transdermal; and non-intramuscular injection in claim 5)
PTSD indication (treatment or symptom-reduction framing)

This structure matters because it sets up the likely prior-art pattern: any single prior-art reference on (a) botulinum toxin for psychiatric symptoms, (b) botulinum toxin for neuropathic/pain pathways, or (c) trigeminal modulation in neuropsychiatric disease may be individually insufficient, but combinations can become decisive under obviousness-type reasoning.

How broad is the claim coverage versus realistic competitors?

Toxin and route breadth

Toxin genus: claim set covers type A and type B. That blocks easy “design-around” by switching between BoNT/A and BoNT/B.
Delivery placements: “subdermal, intradermal or transdermal” plus injection options allows multiple administration styles without leaving the claim perimeter.
Non-intramuscular: still leaves some routes outside the claim if a competitor places toxin into muscle or uses a delivery mechanism that is not “non-intramuscular.” But “non-intramuscular” is a common clinician framing, making it difficult for competitors to plausibly move outside.

Target breadth via nerve branch list

The extended list in claims 7 and 15 includes multiple branches associated with the ophthalmic (V1), maxillary (V2), and mandibular (V3) territories and other named associated branches. In practice, this is designed to cover:

percutaneous sensory-nerve approaches in craniofacial regions,
both direct injection to a branch and techniques that treat the sensory field (especially for claim 8 via “vicinity”).

Dose breadth

Claim 14’s “about 1 unit to about 3,000 units” is extremely wide relative to typical BoNT dosing windows used in focal indications. This makes dose-based “carve-outs” harder for competitors because an argument about “different dosage regime” becomes less persuasive if any therapeutically effective dosing can be mapped into that broad band.

Coverage summary

Design choice	Likely impact on infringement risk
Switching BoNT/A to BoNT/B	Still within claims (2/3, 9/10)
Using injection vs transdermal	Still within dependent claim sets (4/5 vs 6; 11/12)
Treating sensory nerve vicinity vs direct	Still within claim 8 (vicinity)
Avoiding trigeminal altogether (e.g., occipital, vagus)	May reduce risk if outside “trigeminal” targeting
Avoiding non-intramuscular delivery (inject into muscle)	Potential path out, but many facial injections remain non-muscular
Dose-based workaround	Weak, due to wide range (claim 14)

What are the highest-risk claim interpretation points?

“Directly administering … to a trigeminal nerve” (claim 1)

Direct administration is narrower than “vicinity,” but claim 7’s list of branches and the typical clinical definition of facial nerve targeting could still lead to broad claim construction where “direct” includes targeted deposition in close anatomic proximity to a named trigeminal branch.

“Trigeminal sensory nerve” versus “trigeminal nerve” (claim 8)

Claim 8 expressly uses “trigeminal sensory nerve” and includes “vicinity,” broadening the practical capture of techniques that modify sensory signaling without necessarily depositing toxin on the nerve sheath itself.

Non-intramuscular

This term tends to become a factual issue tied to injection plane and intended tissue compartment. If a competitor uses a subdermal/intradermal approach, it will likely map cleanly into “non-intramuscular.” The more plausible carve-out would be explicitly intramuscular delivery, but that would depart from most trigeminal facial injection practices that aim to affect sensory branches.

How does this patent sit in the likely PTSD and neuro-modulation landscape?

PTSD drug and device development has historically focused on:

central neurotransmitter modulation (SSRIs, SNRIs, Prazosin for sleep, antipsychotics in subsets),
trauma-focused psychotherapy plus adjuncts,
and limited neuromodulation modalities.

A botulinum toxin approach is a divergence point because BoNT’s primary known use is peripheral neuromuscular blockade, yet emerging claims in this space often argue downstream effects on sensory-affective processing, stress circuitry, and symptom triggers. This claim set operationalizes that divergence by anchoring the intervention in trigeminal sensory pathways.

From a patent-landscape perspective, that means the best prior-art attacks typically come in two ways:

Indication bridge: prior patents on BoNT for anxiety, PTSD-like disorders, or emotion-related symptoms.
Target bridge: prior patents on BoNT to craniofacial nerves, trigeminal pathways, or sensory modulation for pain or headache disorders, coupled with a rationale that trigeminal sensory signaling impacts psychiatric symptom expression.

Without the prosecution history and without the full specification text, the only defensible reading is the claim architecture itself: it is written to support “direct target, local delivery, PTSD clinical effect” as the technical outcome.

Where are the likely novelty or obviousness vulnerabilities in these claims?

A. Prior art on BoNT for psychiatric symptoms

If any earlier disclosures exist for botulinum toxin treating or reducing symptoms in anxiety, depression, or PTSD, the remaining differentiators become delivery target (trigeminal) and local non-intramuscular administration. Under obviousness theory, a challenger can argue it is predictable to select a craniofacial sensory target to influence stress circuitry.

B. Prior art on trigeminal modulation using BoNT

If earlier disclosures exist for trigeminal modulation (often in migraine, neuralgia, facial pain, or neuropathic pain), challengers can pair:

the known efficacy of BoNT at trigeminal branches for pain or sensory dysfunction, with
a rationale that PTSD symptom triggers overlap sensory/emotional processing pathways.

C. Breadth creates “combination pressure”

Claim 1 is broad in “botulinum toxin” and claim 8 broad in “therapeutically effective amount,” with claim 14 giving a wide numerical band. That combination increases the odds that a prior art dose falls “in the range,” even if the prior art used a different indication, which can support argument that the method is obvious when substituting the indication or symptom goal.

Patent landscape implications for competitors

Potential infringement triggers

A competitor likely faces infringement exposure if they:

treat PTSD (or reduce occurrence of PTSD symptoms),
administer BoNT/A or BoNT/B,
in a non-intramuscular manner,
and target trigeminal branches or their sensory vicinity.

Because claim 8 covers “vicinity,” techniques that do not precisely localize the nerve but deposit toxin in the trigeminal sensory field still have meaningful capture risk.

Where competitors can reduce risk

The most credible design-around is anatomical: targeting a different sensory pathway that is not “trigeminal” (for example, occipital or vagal routes). A second is administrative: ensuring delivery is not “non-intramuscular.” However, for craniofacial routes, many approaches naturally map into subdermal/intradermal or otherwise non-muscular planes, so this is harder to operationalize.

Freedom-to-operate posture (claim set-driven)

If a competitor plans to target trigeminal sensory branches with BoNT/A or BoNT/B in non-muscular planes for PTSD or PTSD symptom reduction, the claim set is directly aligned with their plan.
If a competitor uses another neuromodulation method (e.g., trigeminal stimulation without toxin) the exposure declines because the claims are toxin-delivery-method claims, not apparatus claims.

What matters in enforcement: claim 1 vs claim 8

Claim 1 is the cleaner infringement theory for clinical PTSD treatment. It requires “directly administering” to a trigeminal nerve.
Claim 8 is the more practical theory for clinics because it covers “reducing occurrence of a symptom” and includes “vicinity” of trigeminal sensory nerves. Many real-world protocols may be described in symptom-reduction terms rather than “treating PTSD,” which makes claim 8 particularly important.

Key Takeaways

US Patent 10,064,921 is centered on one technical thesis: botulinum toxin delivery to trigeminal nerves or trigeminal sensory fields, using non-intramuscular/local administration, for PTSD treatment or symptom reduction.
The claim set is broad across toxin type (A and B), administration plane (subdermal/intradermal/transdermal), and target nerve branches; claim 14 adds a wide dosing band.
The enforcement-ready coverage is claim 8, due to “vicinity” language and symptom-occurrence framing.
The most viable competitor design-around is likely anatomic (avoid trigeminal pathways) rather than dosage or toxin-type substitution (because both are covered).

FAQs

1) Does the patent cover both botulinum toxin type A and type B?

Yes. Claims 2-3 cover type A or type B for claim 1, and claims 9-10 do the same for claim 8.

2) Is “subdermal/intradermal/transdermal” part of the claimed delivery?

Yes. Claim 6 (for claim 1) and claim 12 (for claim 8) specify administration as subdermal, intradermal, or transdermal.

3) Can the toxin be injected, or is it only topical/transdermal?

The claims cover both: claim 4 and claim 11 recite injection, while claims 6 and 12 recite subdermal/intradermal/transdermal placement.

4) What makes claim 8 broader than claim 1?

Claim 8 includes botulinum toxin administration to a trigeminal sensory nerve or its vicinity and requires non-intramuscular delivery, plus it targets reduction of symptom occurrence rather than full treatment.

5) Is there a defined dose range?

Yes. Claim 14 recites a therapeutically effective amount between “about 1 unit and about 3,000 units.”

References

United States Patent 10,064,921 (claims as provided by user).

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	December 08, 2000	⤷ Start Trial	2037-03-02
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 10,064,921

Summary for Patent: 10,064,921